Though Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions beyond psoriasis and psoriatic arthritis.
An article from
Dive Brief
Though Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions beyond psoriasis and psoriatic arthritis.
Published Sept. 1, 2026
Alumis shares plunged more than 50% on Sept. 1, 2026.
Alumis falls after TYK2 pill fails lupus study, but CEO sees 'clear path forward'
Alnylam defends heart disease drugs after failure of AstraZeneca’s Wainua
Alnylam's heart drug troubles take center stage at a cardiology conference
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
Alumis' lupus drug misses its Phase 2b goal, sending shares down over 50%, but a high-IFNGS subgroup shows a path toward Phase 3…
Alumis releases long-term data for psoriasis drug envudeucitinib, boasting top skin clearance rates ahead of a Q4 FDA filing with…
An AstraZeneca heart disease trial failure has put Alnylam under pressure. It's mounting a defense of its medicines.
The failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a…
The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A…
Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.
